Free Trial
→ $3,600 gold is nice ... but here’s what most gold bugs are missing (From Weiss Ratings) (Ad)tc pixel

Shield Therapeutics (LON:STX) Trading Up 30.2% - Time to Buy?

Written by MarketBeat
Updated September 10, 2025
Shield Therapeutics logo with Medical background

Key Points

  • Shield Therapeutics shares rose by 30.2% during trading, reaching a high of GBX 8.90 ($0.12) from a previous close of GBX 6.30 ($0.08).
  • Over 25 million shares were traded, which is an 879% increase from the average session volume.
  • The company, known for its Accrufer®/Feraccru® product addressing iron deficiency, currently has a market capitalization of £90.47 million.
  • Interested in Shield Therapeutics? Here are five stocks we like better.

Shares of Shield Therapeutics plc (LON:STX - Get Free Report) were up 30.2% on Friday . The stock traded as high as GBX 8.90 ($0.12) and last traded at GBX 8.20 ($0.11). Approximately 25,560,381 shares were traded during mid-day trading, an increase of 879% from the average daily volume of 2,610,317 shares. The stock had previously closed at GBX 6.30 ($0.09).

Shield Therapeutics Price Performance

The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The firm has a market cap of £79.79 million, a P/E ratio of -383.00 and a beta of 1.42. The company has a 50-day moving average of GBX 5.18 and a 200 day moving average of GBX 3.57.

About Shield Therapeutics

(Get Free Report)

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.

Recommended Stories

Should You Invest $1,000 in Shield Therapeutics Right Now?

Before you consider Shield Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shield Therapeutics wasn't on the list.

While Shield Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.